XML 34 R17.htm IDEA: XBRL DOCUMENT v3.21.2

Note 1 - Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2021

Notes Tables

Debt Securities, Available-for-sale [Table Text Block]

		December 31, 2020
										Gross				Gross
		Amortized				Accrued				Unrealized				Unrealized				Estimated
		Cost				Interest				Gains				Losses				Fair Value
Obligations of U.S. Government and its agencies		$	24,986			$	14			$	3			$	(3	)		$	25,000
Certificates of deposit			3,225				11				3				-				3,239
Total investments		$	28,211			$	25			$	6			$	(3	)		$	28,239

Schedule of Receivables from Collaborations [Table Text Block]

		September 30, 2021
		Billed				Unbilled				Total
U.S. Department of Health and Human Services		$	-			$	3,086			$	3,086
Royalty receivables from partners			200				-				200
Total receivables		$	200			$	3,086			$	3,286

		December 31, 2020
		Billed				Unbilled				Total
U.S. Department of Health and Human Services		$	-			$	5,402			$	5,402
Royalty receivables from partners			2,816				25				2,841
Total receivables		$	2,816			$	5,427			$	8,243

Schedule of Inventory, Current [Table Text Block]

		September 30,				December 31,
		2021				2020
Raw materials		$	6,830			$	206
Work-in-process			6,619				2,555
Finished goods			637				4,548
Total Inventory		$	14,086			$	7,309
Reserves			(423	)			(270	)
Total Inventory, net		$	13,663			$	7,039

Disaggregation of Revenue [Table Text Block]

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2021				2020				2021				2020
Product sales, net:
ORLADEYO		$	36,711			$	-			$	76,023			$	-
RAPIVAB			2,430				11				7,165				11
Peramivir			-				2,467				7,254				2,685
Total product sales, net			39,141				2,478				90,442				2,696
Royalty revenue			322				254				(447	)			2,243
Milestone revenue			-				-				15,000				-
Collaborative and other research and development revenues:
U.S. Department of Health and Human Services			1,531				3,088				5,017				7,240
Torii Pharmaceutical Co., Ltd.			-				282				-				1,617
Total collaborative and other research and development revenues			1,531				3,370				5,017				8,857
Total revenues		$	40,994			$	6,102			$	110,012			$	13,796

X

- Definition

Tabular disclosure representing receivables from collaborations.

+ References

No definition available.

+ Details

Name:	bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock
Namespace Prefix:	bcrx_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928

+ Details

Name:	us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

+ Details

Name:	us-gaap_ScheduleOfInventoryCurrentTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration